TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11683666

Group type: EXPERIMENTAL
Intervention: Epidural blockade with bupivacaine
Number of subjects: 14

Group type: COMPARATOR
Intervention: General anaesthesia with isoflurane (control group)
Number of subjects: 14
Study: 9538962

Group type: EXPERIMENTAL
Intervention: Intermittent very‐low‐calorie diet (VLCD) for 5 consecutive days during week 2, followed by intermittent VLCD therapy for 1 day/week for 15 weeks (1‐day) or for 5 consecutive days every 5 weeks (5‐day)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intermittent VLCD therapy for 5 consecutive days every 5 weeks (5‐day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard behavioral therapy (SBT) group with a 1,500‐1,800 kcal/day diet throughout
Number of subjects: 54
Study: 8273801

Group type: EXPERIMENTAL
Intervention: Smoking two cigarettes during the late phase of GB emptying (S20-40)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Smoking two cigarettes during the early phase of GB emptying (S0-20)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control test without smoking (C)
Number of subjects: 10
Study: 2644344

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Amineptine
Number of subjects: 63
Study: 790412

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 0
Study: 31274007

Group type: EXPERIMENTAL
Intervention: Counseling (1-3 individual and 6 group sessions)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 80
Study: 30031368

Group type: EXPERIMENTAL
Intervention: Graded in vivo exposure (EXP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 12
Study: 27603948

Group type: EXPERIMENTAL
Intervention: Vibrax (mechanical vibrations) applied for 5 minutes
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (CG) received cardiovascular training with mobilization and active breathing exercises
Number of subjects: 23
Study: 23832167

Group type: EXPERIMENTAL
Intervention: Scapular function training (SFT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 22561380

Group type: EXPERIMENTAL
Intervention: Individualized task-oriented ambulation training (30-45 mins, three times a week for 4 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine nursing care (control group)
Number of subjects: 50
Study: 20569068

Group type: EXPERIMENTAL
Intervention: Higher-dose BoNTA (200-240 U)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Lower-dose BoNTA (120-150 U)
Number of subjects: 109

Group type: COMPARATOR
Intervention: BoNTA (both doses)
Number of subjects: 109
Study: 18502002

Group type: EXPERIMENTAL
Intervention: NYVAC-C (20 participants)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (4 participants)
Number of subjects: 24
Study: 15992393

Group type: EXPERIMENTAL
Intervention: Bright light therapy (10,000 lux, 1 h daily)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Dim light therapy (50 lux, 30 min daily)
Number of subjects: 102
Study: 12849763

Group type: EXPERIMENTAL
Intervention: Focal cerebellar lesions
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control subjects (matched for age, gender, and years of education)
Number of subjects: 16
Study: 10499749

Group type: EXPERIMENTAL
Intervention: 500 mL 6% hetastarch (group H)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1500 mL lactated Ringer's solution (group R)
Number of subjects: 24
Study: 9030391

Group type: EXPERIMENTAL
Intervention: 3TC and zidovudine combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 0
Study: 1800872

Group type: EXPERIMENTAL
Intervention: 0.025 mg intrathecal morphine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 0.05 mg intrathecal morphine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 0.075 mg intrathecal morphine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 0.1 mg intrathecal morphine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 0.125 mg intrathecal morphine
Number of subjects: 63

Group type: COMPARATOR
Intervention: 0 mg intrathecal morphine (control)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 0.025 mg to 0.125 mg intrathecal morphine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 0.075 mg to 0.125 mg intrathecal morphine
Number of subjects: 63
Study: 6323335

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg nightly)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg nightly)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Antacids as needed for symptomatic relief
Number of subjects: 110
Study: 30859976

Group type: EXPERIMENTAL
Intervention: PGx-guided care arm
Number of subjects: 1167

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) arm
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: PGx-guided care arm (incongruent to congruent medication change)
Number of subjects: 1167
Study: 29493798

Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (MHT)
Number of subjects: 0
Study: 27021502

Group type: EXPERIMENTAL
Intervention: Wire-grasping method
Number of subjects: 28

Group type: COMPARATOR
Intervention: Direct method
Number of subjects: 28
Study: 24601857

Group type: EXPERIMENTAL
Intervention: SALT
Number of subjects: 43

Group type: COMPARATOR
Intervention: JumpSTART
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 43
Study: 22878451

Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ranibizumab 0.5 mg
Number of subjects: 9
Study: 20805299

Group type: EXPERIMENTAL
Intervention: Saracatinib 175 mg once daily
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Saracatinib 50 mg once daily
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Saracatinib 125 mg once daily
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 81
Study: 17295731

Group type: EXPERIMENTAL
Intervention: Brief skills training program (BSTP)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Twelve-step-influenced (TSI) program
Number of subjects: 556

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 556
Study: 15699376

Group type: EXPERIMENTAL
Intervention: 20 mg of IV metoclopramide, given up to four times over 2 hours
Number of subjects: 78

Group type: COMPARATOR
Intervention: 6 mg of subcutaneous sumatriptan
Number of subjects: 78
Study: 11875637

Group type: EXPERIMENTAL
Intervention: 10 g branch chain amino acids
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 g branch chain amino acids
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 60 g branch chain amino acids
Number of subjects: 12
Study: 10195774

Group type: EXPERIMENTAL
Intervention: DTaP
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: DTP-PRP-T
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: DTaP-PRP-T
Number of subjects: 930

Group type: COMPARATOR
Intervention: Whole cell pertussis vaccine
Number of subjects: 930

Group type: COMPARATOR
Intervention: Acellular pertussis vaccine
Number of subjects: 930
Study: 7781259

Group type: EXPERIMENTAL
Intervention: Torsemide (10 mg orally and intravenously)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Furosemide (40 mg orally and 20 mg intravenously)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 16

Group type: COMPARATOR
Intervention: All four treatments (torsemide and furosemide in both oral and intravenous forms)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Torsemide and Furosemide
Number of subjects: 16
Study: 2184187

Group type: EXPERIMENTAL
Intervention: Interdisciplinary geriatric assessment
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (no geriatric assessment)
Number of subjects: 142
Study: 653509

Group type: EXPERIMENTAL
Intervention: Calcitonin (0.16 microgram/kg/h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcitonin (0.32 microgram/kg/h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.15M NaCl (Control)
Number of subjects: 0
Study: 30950637

Group type: EXPERIMENTAL
Intervention: Individually titrated stimulant medication (MSM) for 8 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Behavioral parent training (BPT) for 8 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combined treatment after initial treatment (MSM or BPT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Monotherapy treatment visits (MSM-MSM, BPT-BPT)
Number of subjects: 35
Study: 29037483

Group type: EXPERIMENTAL
Intervention: 2014 guidelines for labor management
Number of subjects: 7845

Group type: COMPARATOR
Intervention: 2010 guidelines for labor management
Number of subjects: 7845
Study: 25449654

Group type: EXPERIMENTAL
Intervention: Dabrafenib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dabrafenib with ketoconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dabrafenib with gemfibrozil
Number of subjects: 0
Study: 23842127

Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: sustained HIV-1 RNA suppression below 400 copies/ml
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: CD4 testing
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: continued testing for CD4 cell count after 48 weeks
Number of subjects: 689
Study: 21968873

Group type: EXPERIMENTAL
Intervention: Grip work estimation (GW)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Grip strength (GS), Fatigue resistance (FR), Grip work (GW), GW corrected for body weight (GW/BW)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Circulating IL-6
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: TNF-alpha
Number of subjects: 291
Study: 20031714

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 2271

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 2271
Study: 16461819

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg daily for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 80
Study: 15306578

Group type: EXPERIMENTAL
Intervention: OAC treatment (omeprazole, amoxicillin, and clarithromycin)
Number of subjects: 587

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 587
Study: 11159890

Group type: EXPERIMENTAL
Intervention: 4 microg/kg IL-10
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 20 microg/kg IL-10
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (group 0)
Number of subjects: 144
Study: 9692659

Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 12
Study: 7889644

Group type: EXPERIMENTAL
Intervention: In situ hybridization on fetal nucleated cells in maternal whole venous blood
Number of subjects: 39
Study: 2883683

Group type: EXPERIMENTAL
Intervention: Zotepine high dosage (270 mg +/- 37 mg/die)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Zotepine low dosage (168 mg +/- 15 mg/die)
Number of subjects: 20
Study: 31046033

Group type: EXPERIMENTAL
Intervention: 1,000 mg of standardized Withania somnifera extract (WSE)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 29641221

Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional low-tidal volume ventilation (LoTV)
Number of subjects: 52
Study: 27572953

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 9013

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 9013
Study: 25353657

Group type: EXPERIMENTAL
Intervention: .12% chlorhexidine spray
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 26
Study: 22760564

Group type: EXPERIMENTAL
Intervention: Vitamin D (800 IU/d)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 19953428

Group type: EXPERIMENTAL
Intervention: Unilateral deep brain stimulation (DBS) surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (PD controls)
Number of subjects: 24
Study: 17884515

Group type: EXPERIMENTAL
Intervention: Systemic antibiotic therapy
Number of subjects: 2932
Study: 15336816

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/day
Number of subjects: 329

Group type: COMPARATOR
Intervention: Dietary control
Number of subjects: 329
Study: 10901565

Group type: EXPERIMENTAL
Intervention: Normal umbilical artery Doppler studies (n = 109)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Abnormal umbilical artery Doppler studies (n = 77)
Number of subjects: 186
Study: 9333146

Group type: EXPERIMENTAL
Intervention: Cidofovir (0.3% or 1%) gel applied once daily for 5 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cidofovir (0.3% or 1%) gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 30
Study: 8469191

Group type: COMPARATOR
Intervention: Mefloquine (250 mg weekly)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily) and primaquine (7.5 mg daily)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Doxycycline (50 mg daily) and chloroquine (300 mg weekly)
Number of subjects: 413
Study: 3026264

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 69

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Enalapril plus Hydrochlorothiazide
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 69
Study: 2438962

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Methysergide
Number of subjects: 14

Group type: COMPARATOR
Intervention: Chlorpheniramine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Serotonin challenge
Number of subjects: 14
Study: 31567929

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation with sphincter-preserving surgery
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Relative increments of width of presacral space
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Relative increments of thickness of rectal wall
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Relative increments of distal end of sigmoid colon
Number of subjects: 125
Study: 28166296

Group type: EXPERIMENTAL
Intervention: FDC Soli 6 mg + TOCAS
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: FDC Soli 9 mg + TOCAS
Number of subjects: 1208

Group type: COMPARATOR
Intervention: TOCAS alone
Number of subjects: 1208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Overall FDC Soli + TOCAS
Number of subjects: 1208
Study: 25183340

Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg gadobenate dimeglumine
Number of subjects: 28

Group type: COMPARATOR
Intervention: 0.2 mmol/kg gadopentetate dimeglumine
Number of subjects: 28
Study: 23307659

Group type: EXPERIMENTAL
Intervention: Ataxic patients performing U-turns
Number of subjects: 9

Group type: COMPARATOR
Intervention: Controls performing U-turns
Number of subjects: 9
Study: 20464461

Group type: EXPERIMENTAL
Intervention: Microneedle devices (steel, silicon, and polymer) applied to skin
Number of subjects: 2
Study: 18274887

Group type: EXPERIMENTAL
Intervention: Single dose of 300 mg Ginkgo biloba extract (GBE)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Long-term GBE (300 mg/daily) combined with sex therapy
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Sex therapy alone
Number of subjects: 99

Group type: COMPARATOR
Intervention: Long-term GBE administration alone
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 16627376

Group type: EXPERIMENTAL
Intervention: Acarbose, 100 mg three times a day
Number of subjects: 1368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 1368
Study: 15531004

Group type: EXPERIMENTAL
Intervention: Delapril 30 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Enalapril 20 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Delapril + Manidipine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Enalapril + HCTZ
Number of subjects: 160
Study: 11060816

Group type: EXPERIMENTAL
Intervention: Antibiotics or antiviral agents (specific regimens not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 9262270

Group type: EXPERIMENTAL
Intervention: Humegon
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Pergonal
Number of subjects: 181
Study: 8328663

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 2868172

Group type: EXPERIMENTAL
Intervention: New measurement technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Established measurement technique
Number of subjects: 0
Study: 29641467

Group type: EXPERIMENTAL
Intervention: Medium adherence to the Mediterranean diet
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Third quartile of the 'Western pattern' dietary pattern
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Fourth quartile of the 'Western pattern' dietary pattern
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Third quartile of the 'prudent pattern' dietary pattern
Number of subjects: 539
Study: 26714115

Group type: EXPERIMENTAL
Intervention: MedXL 0.9% sodium chloride flush
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Becton-Dickinson 0.9% sodium chloride flush
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride flush through central venous access devices
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy volunteers tasting 0.9% sodium chloride from prefilled syringes
Number of subjects: 75
Study: 25638303

Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg twice daily (BID)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 24296323

Group type: EXPERIMENTAL
Intervention: Etamicastat 50 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Etamicastat 100 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Etamicastat 200 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 20964860

Group type: EXPERIMENTAL
Intervention: Virtual Infant Parenting (VIP) program administered in intervention schools to 1,267 participants.
Number of subjects: 2834

Group type: COMPARATOR
Intervention: Standard curriculum received by 1,567 participants in non-intervention schools.
Number of subjects: 2834
Study: 18211527

Group type: EXPERIMENTAL
Intervention: Telephone survey (with web follow-up for nonrespondents)
Number of subjects: 751

Group type: COMPARATOR
Intervention: Web survey (with telephone follow-up)
Number of subjects: 751
Study: 16597501

Group type: EXPERIMENTAL
Intervention: Carbamazepine treatment (active group, n=33)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo treatment (control group, n=30)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Carbamazepine monotherapy (following open-label treatment)
Number of subjects: 63
Study: 14664880

Group type: EXPERIMENTAL
Intervention: Total abdominal hysterectomy
Number of subjects: 319

Group type: COMPARATOR
Intervention: Subtotal abdominal hysterectomy
Number of subjects: 319
Study: 10751097

Group type: EXPERIMENTAL
Intervention: Cycling endurance test A1 at 78% peak O2 consumption (VO2peak)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cycling endurance test A2 at 78% peak O2 consumption (VO2peak)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cycling endurance test B2 at 78% peak O2 consumption (VO2peak)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cycling endurance test C2 at 78% peak O2 consumption (VO2peak)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Breathing pattern of test A2
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Breathing pattern of test B2
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Breathing pattern of test C2
Number of subjects: 8
Study: 8659784

Group type: EXPERIMENTAL
Intervention: 10 microg/kg mivacurium
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 70 microg/kg mivacurium
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (ED95 dose of 100 microg/kg mivacurium)
Number of subjects: 41
Study: 1356024

Group type: EXPERIMENTAL
Intervention: alpha‐methyl‐para‐tyrosine (AMPT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation + AMPT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Total sleep deprivation + Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 40.5 h of rest + AMPT
Number of subjects: 40

Group type: COMPARATOR
Intervention: 40.5 h of rest + Placebo
Number of subjects: 40
Study: 3921934

Group type: EXPERIMENTAL
Intervention: Cephalexin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Dicloxacillin
Number of subjects: 21
Study: 29725749

Group type: EXPERIMENTAL
Intervention: Computer-assisted cryotherapy at 10-12 °C (Cold-group, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Computer-assisted cryotherapy at 21 °C (Warm-group, n=30)
Number of subjects: 60
Study: 29515151

Group type: EXPERIMENTAL
Intervention: Rectal swab samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stool samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mucosal samples
Number of subjects: 0
Study: 27832025

Group type: EXPERIMENTAL
Intervention: 500 mg valacyclovir twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24456909

Group type: EXPERIMENTAL
Intervention: Silexan 160 mg/d
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Silexan 80 mg/d
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/d
Number of subjects: 539

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study: 23158561

Group type: EXPERIMENTAL
Intervention: Continuous interscalene brachial plexus block plus general anesthesia (ISB + GA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia alone (GA)
Number of subjects: 60